Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Law firm asks for structure/function petition decision

This article was originally published in The Tan Sheet

Executive Summary

The dietary supplement industry would have no reporting burden for structure/function claim notifications if FDA affirmed a citizen petition to revoke the claim notification rule, A. Wes Siegner says. The Hyman, Phelps & McNamara attorney reminded FDA in a Nov. 23 1letter that the agency has not responded to HPM's Feb. 4, 2000, petition, which asked FDA to rescind its disclaimer requirement for structure/function claims and its requirement that supplement firms notify FDA of such claims, as long as the claims are "truthful, non-misleading and derive[d] from nutritive value." Siegner's letter responds to FDA's June 2 Federal Register notice seeking comment on the burden of claim notification - estimated at 1,650 total hours annually (2"The Tan Sheet" June 8, 2009)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel